Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 27 citing articles:

Obesity and cardiovascular disease: an ESC clinical consensus statement
Konstantinos C. Koskinas, Emeline M. Van Craenenbroeck, Charalambos Antoniades, et al.
European Heart Journal (2024)
Open Access | Times Cited: 53
Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events: A Cross-Sectional Analysis of the National Institutes of Health All of Us Cohort
Wafa Ali Aldhaleei, Tadesse Melaku Abegaz, Akshaya Srikanth Bhagavathula
Pharmaceuticals (2024) Vol. 17, Iss. 2, pp. 199-199
Open Access | Times Cited: 22
Obesity and cardiovascular disease: an ESC clinical consensus statement
Konstantinos C. Koskinas, Emeline M. Van Craenenbroeck, Charalambos Antoniades, et al.
European Journal of Preventive Cardiology (2024)
Open Access | Times Cited: 16
How ‘miracle’ weight‐loss semaglutide promises to change medicine but can we afford the expense?
Ralf Weiskirchen, Amedeo Lonardo
British Journal of Pharmacology (2025)
Open Access | Times Cited: 3
Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes
Alan Y. Hsu, Hou‐Ting Kuo, Yu-Hsun Wang, et al.
JAMA Ophthalmology (2025)
Closed Access | Times Cited: 3
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Wen‐Jing Xiao, Wenjie Jiang, Zheng Chen, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 2
An overview of obesity‐related complications: The epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes
Matthias Blüher
Diabetes Obesity and Metabolism (2025)
Open Access | Times Cited: 2
Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: a systematic review and meta-analysis of randomized controlled trials
Ligang Liu, Hekai Shi, Merilyn Xie, et al.
International Journal of Clinical Pharmacy (2024) Vol. 46, Iss. 6, pp. 1268-1280
Open Access | Times Cited: 9
Therapeutic Advances in Obesity: How Real-World Evidence Impacts Affordability Beyond Standard of Care
Dimitrios Patoulias, Theocharis Koufakis, Ieva Ruža, et al.
Pragmatic and Observational Research (2024) Vol. Volume 15, pp. 139-149
Open Access | Times Cited: 6
The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study
Mojca Jensterle, Simona Ferjan, Andrej Janež
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 5
Tackling the complexity of obesity in the US through adaptation of public health strategies
Jamy D. Ard, Amber Huett-Garcia, Michele Bildner
Frontiers in Public Health (2025) Vol. 13
Open Access
From Childhood Obesity to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Hyperlipidemia Through Oxidative Stress During Childhood
Siham Accacha, Julia Barillas-Cerritos, Ankita Srivastava, et al.
Metabolites (2025) Vol. 15, Iss. 5, pp. 287-287
Open Access
Once‐Weekly Semaglutide Versus Once‐Daily Liraglutide for Weight Loss in Adults: A Meta‐Analysis of Randomized Controlled Trials
Tallal Mushtaq Hashmi, Mushood Ahmed, Ali Haider, et al.
Clinical and Translational Science (2025) Vol. 18, Iss. 2
Open Access
Weight and mortality in people living with HIV and heart failure: Obesity paradox in the era of glucagon‐like peptide 1 (GLP‐1) receptor agonists and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors
Н. А. Назаренко, Yi‐Yun Chen, Paweł Borkowski, et al.
HIV Medicine (2025)
Closed Access
Effect of semaglutide with obesity or overweight individuals without diabetes: an Umbrella review of systematic reviews
Xiaoye Hu, Yongsheng Wang, Kehu Yang, et al.
Endocrine (2025)
Closed Access
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
Richard Salvador, Carla Moutinho, Carla Silva, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 399-399
Open Access
Tirzepatide vs semaglutide and liraglutide for weight loss in patients with overweight or obesity without diabetes: A short-term cost-effectiveness analysis in the United States
Ligang Liu, Jiayu Cui, Marjorie V. Neidecker, et al.
Journal of Managed Care & Specialty Pharmacy (2025) Vol. 31, Iss. 5, pp. 441-450
Closed Access
The Efficacy and Safety of Semaglutide-Based Medications for Long-Term Weight Loss and Cardiovascular Health
Sadaf Khalid, Marek Malík, Marium Khan, et al.
Pakistan Journal of Health Sciences (2025)
Closed Access
Semaglutide in Psychiatry—Opportunities and Challenges
Sri Mahavir Agarwal, Margaret Hahn
JAMA Psychiatry (2024) Vol. 81, Iss. 10, pp. 955-955
Closed Access | Times Cited: 3
Efficacy and safety of tirzepatide in overweight or obese adults without diabetes: systematic review and meta-analysis of randomized controlled trials
Ligang Liu, Milap C. Nahata, Hekai Shi, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 2
Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis
Gilson Pires Dorneles, Ellen Algeri, Gerhard Lauterbach, et al.
Experimental and Clinical Endocrinology & Diabetes (2024) Vol. 132, Iss. 06, pp. 316-327
Closed Access | Times Cited: 2
An Assessment of Semaglutide Safety Based on Real World Data: From Popularity to Spontaneous Reporting in EudraVigilance Database
Anca Butucă, Carmen Maximiliana Dobrea, Anca Maria Arseniu, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1124-1124
Open Access | Times Cited: 2
Effects of Semaglutide in Doxorubicin-Induced Cardiac Toxicity in Wistar Albino Rats
Raz HamaSalih
Cancer Management and Research (2024) Vol. Volume 16, pp. 731-740
Open Access | Times Cited: 2
An exploratory analysis of glucagon‐like peptide‐1 (GLP‐1) agonists and biosimilars: A literature review
Jimmy Wen, Adam Razick, Christiane How‐Volkman, et al.
Diabetes Obesity and Metabolism (2024)
Closed Access | Times Cited: 2
The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression
Moein Ala, Mohammadreza Moheb Aleaba
Journal of Endocrinological Investigation (2024)
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top